Investor and Media Relations
info@keli.eu
Seed CLA diligence, data room, media inquiries, press
Direct routing to executive functions.
Investors, partners, clinicians, and patients each engage with a dedicated KELI function. Please use the contact directory below.
Contact directory.
Business Development and Partnerships
info@keli.eu
Pharma co-development, licensing
Patient Enquiries
patients@keli.eu
RECARTA eligibility, KELI-101 trial information, clinical access
General
info@keli.eu
All other correspondence
General inquiry.
For investor relations, business development, and partnership inquiries.
info@keli.eu
Patient enquiries. Direct access.
Patients and referring clinicians may contact KELI directly for information about RECARTA eligibility, the KELI-101 clinical trial, and clinical access pathways. All patient enquiries are handled by KELI clinical operations under GDPR Art. 9(2)(h).
RECARTA · Cartilage Repair
Autologous chondrocyte therapy
RECARTA is approved under EU Hospital Exemption in Lithuania, with product-specific ATMP manufacturing permit No. 25. Patients with focal articular cartilage defects may be referred by their orthopaedic surgeon for eligibility assessment. Regulatory credentials
- Focal cartilage defects
- Knee · Ankle · Shoulder
- Lithuania
patients@keli.eu
KELI-101 · Phase 1b/2 Trial
Placental MSC therapy for AKI following cardiac surgery
KELI-101: CTA in preparation, not submitted, not enrolling. First patient planned Q2 2027, subject to CTA approval. EU CTR 2026-527099-98-00 identifies the planned study. KELI-101 is manufactured in-house at LUHS. Trial enquiries do not constitute screening or enrolment.
- Cardiac surgery patients
- AKI prevention
- Phase 1b/2 planned
patients@keli.eu
For RECARTA eligibility or information about the planned KELI-101 study, contact patients@keli.eu. Submitting an enquiry is not clinical screening or trial enrolment.
Patient eligibilityPatient eligibility
For RECARTA and information about the planned KELI-101 study.
patients@keli.eu